About

Antimicrobial resistance is one of the biggest public health challenges of our time and fighting this serious threat is a priority that requires a collaborative approach across all sectors. BioInfect will look at the critical issues relating to the development of new anti-infectives, the endemic problem of resistance and the considerations for creating a truly global and effective response to antimicrobial resistance.

Antimicrobial resistance today
Antimicrobial resistance arises when the organisms that cause infection evolve ways to survive treatment. Once standard treatments are ineffective, it is easier for infections to persist and spread. These resistant organisms can be found in people, animals, food and the environment. The rise and spread of antimicrobial resistance are creating a new generation of ‘superbugs’ that cannot be treated with existing medicines. 

Drug-resistant bacteria infect over 50m people worldwide killing over 700,000 people each year. Without effective antibiotics, even minor surgery and routine operations could become high-risk procedures if serious infections can’t be treated.

2020 Attendees
In 2020 we welcomed delegates from Roche, Pfizer, Ineos Oxford Institute, TB Alliance, Infex Therapeutics, Evotec, Liverpool School of Tropical Medicine, Antibiotic Research UK, Medicines Discovery Catapult, Pro-Lab Diagnostics, NHS, BIVDA, University of Cambridge, Biotaspheric, Destiny Pharma, Alder Hey Children's NHS Foundation Trust, Cresset Discovery Services, NICE, Global AMR R&D Hub, Innovation Agency, Mutabilis, Vedanta Biosciences, AMR Action Fund, Knowledge Transfer Network, Apis Assay Technologies, Northumbria University, Withers & Rogers, BMG Labtech, University of Huddersfield, University of Manchester, AF ChemPharm, SRG, Sai Life Sciences, Durham University, University of Leeds, IN.PACT eK, Bio2Business, RSM, Melhor Consulting, Alderley Park Ltd and MFT.

Further details will be available shortly.